Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of asunaprevir + daclatasvir in chronic hepatitis C genotype 1b
NL-OMON37621Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asunaprevir and daclatasvir in chronic hepatitis C (CHC) (3 arms), sponsored by Bristol Myers Squibb. Started Aug 2012; status: active, not recruiting.
02
Drugs
asunaprevirdaclatasvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NL-OMON37621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37621.